HRP20090677T1 - Derivati 5-piridinil-1-azabiciklo[3.2.1]oktana, postupak njihovog dobivanja i njihova upotreba kao terapijskih sredstava - Google Patents
Derivati 5-piridinil-1-azabiciklo[3.2.1]oktana, postupak njihovog dobivanja i njihova upotreba kao terapijskih sredstava Download PDFInfo
- Publication number
- HRP20090677T1 HRP20090677T1 HR20090677T HRP20090677T HRP20090677T1 HR P20090677 T1 HRP20090677 T1 HR P20090677T1 HR 20090677 T HR20090677 T HR 20090677T HR P20090677 T HRP20090677 T HR P20090677T HR P20090677 T1 HRP20090677 T1 HR P20090677T1
- Authority
- HR
- Croatia
- Prior art keywords
- azabicyclo
- pyrid
- octane
- compound
- formula
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract 8
- 238000002360 preparation method Methods 0.000 title claims 7
- UUWGRAXIISRCMS-UHFFFAOYSA-N 5-pyridin-2-yl-1-azabicyclo[3.2.1]octane Chemical class C1N(CCC2)CCC21C1=CC=CC=N1 UUWGRAXIISRCMS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 44
- 150000003839 salts Chemical class 0.000 claims abstract 11
- 239000012453 solvate Substances 0.000 claims abstract 11
- 239000002253 acid Substances 0.000 claims abstract 10
- 238000000034 method Methods 0.000 claims abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- QUIJMHDIAFOPRK-UHFFFAOYSA-N 1-cyclooctylazocane Chemical group C1CCCCCCC1N1CCCCCCC1 QUIJMHDIAFOPRK-UHFFFAOYSA-N 0.000 claims 8
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims 6
- 125000001425 triazolyl group Chemical group 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- -1 cyano, hydroxyl Chemical group 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims 3
- 239000003054 catalyst Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 229910052763 palladium Inorganic materials 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 210000003141 lower extremity Anatomy 0.000 claims 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 230000003313 weakening effect Effects 0.000 claims 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical class [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- XZBIXDPGRMLSTC-UHFFFAOYSA-N formohydrazide Chemical compound NNC=O XZBIXDPGRMLSTC-UHFFFAOYSA-N 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 claims 1
- 210000003625 skull Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
- 201000002282 venous insufficiency Diseases 0.000 claims 1
- 235000005074 zinc chloride Nutrition 0.000 claims 1
- 239000011592 zinc chloride Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0508528A FR2889701B1 (fr) | 2005-08-12 | 2005-08-12 | Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation en therapeutique. |
| PCT/FR2006/001912 WO2007020344A1 (fr) | 2005-08-12 | 2006-08-07 | DÉRIVÉS DE δ-PYRIDINYL-i-AZABICYCLO[3.2.1]OCTANE, A LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090677T1 true HRP20090677T1 (hr) | 2010-01-31 |
Family
ID=36273387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090677T HRP20090677T1 (hr) | 2005-08-12 | 2009-12-17 | Derivati 5-piridinil-1-azabiciklo[3.2.1]oktana, postupak njihovog dobivanja i njihova upotreba kao terapijskih sredstava |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US7863290B2 (de) |
| EP (1) | EP1915375B1 (de) |
| JP (1) | JP5164841B2 (de) |
| KR (1) | KR101299339B1 (de) |
| CN (1) | CN101238125B (de) |
| AT (1) | ATE444964T1 (de) |
| AU (1) | AU2006281341B2 (de) |
| BR (1) | BRPI0614623A2 (de) |
| CA (1) | CA2617828C (de) |
| CR (1) | CR9625A (de) |
| CY (1) | CY1109717T1 (de) |
| DE (1) | DE602006009668D1 (de) |
| DK (1) | DK1915375T3 (de) |
| DO (1) | DOP2006000180A (de) |
| EA (1) | EA014023B1 (de) |
| EC (1) | ECSP088170A (de) |
| ES (1) | ES2332472T3 (de) |
| FR (1) | FR2889701B1 (de) |
| GT (1) | GT200600368A (de) |
| HK (1) | HK1120788A1 (de) |
| HN (1) | HN2008000090A (de) |
| HR (1) | HRP20090677T1 (de) |
| IL (1) | IL188796A (de) |
| JO (1) | JO2583B1 (de) |
| MA (1) | MA30200B1 (de) |
| ME (1) | ME01750B (de) |
| MX (1) | MX2008001968A (de) |
| MY (1) | MY147846A (de) |
| NO (1) | NO20081151L (de) |
| NZ (1) | NZ565149A (de) |
| PE (1) | PE20070339A1 (de) |
| PL (1) | PL1915375T3 (de) |
| PT (1) | PT1915375E (de) |
| RS (1) | RS51068B (de) |
| SI (1) | SI1915375T1 (de) |
| TN (1) | TNSN07472A1 (de) |
| TW (1) | TWI324158B (de) |
| UA (1) | UA92917C2 (de) |
| UY (1) | UY29744A1 (de) |
| WO (1) | WO2007020344A1 (de) |
| ZA (1) | ZA200800958B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2912404B1 (fr) * | 2007-02-09 | 2009-04-10 | Sanofi Aventis Sa | Derives d'azabicycloalkane,leur preparation et leur application en therapeutique. |
| GB0817424D0 (en) | 2008-09-24 | 2008-10-29 | Medivir Ab | Protease inhibitors |
| JP2017114765A (ja) * | 2014-04-25 | 2017-06-29 | 大正製薬株式会社 | トリアゾリルで置換されたヘテロアリール化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817679A (en) * | 1993-04-01 | 1998-10-06 | University Of Virginia | 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands |
| EP0664293A1 (de) * | 1993-12-24 | 1995-07-26 | Duphar International Research B.V | 2-Phenyl-7-azabicycloheptane und 6-Phenyl-8-azabicyclo-octane |
| ATE267199T1 (de) * | 1997-05-30 | 2004-06-15 | Neurosearch As | 8-azabicyclo(3,2,1)oct-2-en- und octanderivate als liganden der nicotinergen ach rezeptoren |
| FR2834511B1 (fr) | 2002-01-07 | 2004-02-13 | Sanofi Synthelabo | Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique |
-
2005
- 2005-08-12 FR FR0508528A patent/FR2889701B1/fr active Active
-
2006
- 2006-07-08 UA UAA200802988A patent/UA92917C2/uk unknown
- 2006-07-26 JO JO2006252A patent/JO2583B1/en active
- 2006-08-02 DO DO2006000180A patent/DOP2006000180A/es unknown
- 2006-08-07 MX MX2008001968A patent/MX2008001968A/es active IP Right Grant
- 2006-08-07 AT AT06794298T patent/ATE444964T1/de active
- 2006-08-07 ZA ZA200800958A patent/ZA200800958B/xx unknown
- 2006-08-07 KR KR1020087003271A patent/KR101299339B1/ko not_active IP Right Cessation
- 2006-08-07 WO PCT/FR2006/001912 patent/WO2007020344A1/fr active Application Filing
- 2006-08-07 ME MEP-2009-576A patent/ME01750B/me unknown
- 2006-08-07 CA CA2617828A patent/CA2617828C/fr not_active Expired - Fee Related
- 2006-08-07 RS RSP-2009/0576A patent/RS51068B/sr unknown
- 2006-08-07 ES ES06794298T patent/ES2332472T3/es active Active
- 2006-08-07 EP EP06794298A patent/EP1915375B1/de active Active
- 2006-08-07 PT PT06794298T patent/PT1915375E/pt unknown
- 2006-08-07 EA EA200800575A patent/EA014023B1/ru not_active IP Right Cessation
- 2006-08-07 DE DE602006009668T patent/DE602006009668D1/de active Active
- 2006-08-07 AU AU2006281341A patent/AU2006281341B2/en not_active Ceased
- 2006-08-07 SI SI200630515T patent/SI1915375T1/sl unknown
- 2006-08-07 PL PL06794298T patent/PL1915375T3/pl unknown
- 2006-08-07 NZ NZ565149A patent/NZ565149A/en not_active IP Right Cessation
- 2006-08-07 BR BRPI0614623-6A patent/BRPI0614623A2/pt not_active IP Right Cessation
- 2006-08-07 CN CN2006800291833A patent/CN101238125B/zh not_active Expired - Fee Related
- 2006-08-07 JP JP2008525599A patent/JP5164841B2/ja not_active Expired - Fee Related
- 2006-08-07 DK DK06794298.7T patent/DK1915375T3/da active
- 2006-08-10 PE PE2006000974A patent/PE20070339A1/es not_active Application Discontinuation
- 2006-08-10 MY MYPI20063888A patent/MY147846A/en unknown
- 2006-08-10 GT GT200600368A patent/GT200600368A/es unknown
- 2006-08-11 TW TW095129651A patent/TWI324158B/zh not_active IP Right Cessation
- 2006-08-11 UY UY29744A patent/UY29744A1/es not_active Application Discontinuation
-
2007
- 2007-12-14 TN TNP2007000472A patent/TNSN07472A1/en unknown
- 2007-12-20 CR CR9625A patent/CR9625A/es unknown
-
2008
- 2008-01-15 IL IL188796A patent/IL188796A/en not_active IP Right Cessation
- 2008-01-22 HN HN2008000090A patent/HN2008000090A/es unknown
- 2008-02-11 EC EC2008008170A patent/ECSP088170A/es unknown
- 2008-02-11 US US12/028,999 patent/US7863290B2/en not_active Expired - Fee Related
- 2008-03-04 NO NO20081151A patent/NO20081151L/no not_active Application Discontinuation
- 2008-03-07 MA MA30724A patent/MA30200B1/fr unknown
- 2008-11-11 HK HK08112365.4A patent/HK1120788A1/xx not_active IP Right Cessation
-
2009
- 2009-12-17 HR HR20090677T patent/HRP20090677T1/hr unknown
-
2010
- 2010-01-05 CY CY20101100013T patent/CY1109717T1/el unknown
- 2010-11-29 US US12/955,389 patent/US8541440B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5719773B2 (ja) | 末梢オピオイド受容体アンタゴニストおよびその使用 | |
| US20090181998A1 (en) | Opioid receptor subtype-selective agents | |
| UA120571C2 (uk) | Алостеричні модулятори нікотинових ацетилхолінових рецепторів | |
| JP2009538867A (ja) | 新規１，４−ジアザ−ビシクロ［３．２．２］ノニルオキサジアゾリル誘導体及びそれらの医学的使用 | |
| JP2005508872A (ja) | トロパン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害剤として使用する方法 | |
| HRP20090677T1 (hr) | Derivati 5-piridinil-1-azabiciklo[3.2.1]oktana, postupak njihovog dobivanja i njihova upotreba kao terapijskih sredstava | |
| JP2006519208A (ja) | 新規ジアザビシクロアリール誘導体 | |
| JP2021506916A (ja) | Ｋｅａｐ１のＢＴＢドメインの小分子モジュレータ | |
| CN111107846A (zh) | 烟碱乙酰胆碱受体的杂芳基变构调节剂 | |
| EP1575960B1 (de) | 1,4-diazabicyclo¬3.2.2 nonanecarboxamides derivate, deren herstellung, und deren therapeutische verwendung im zusammenhang mit nikotinischen rezeptor-störungen | |
| HRP20110043T1 (hr) | Derivati 5-piridazinil-1-azabiciklo[3.2.1]oktana, njihovo dobivanje i njihova upotreba u terapiji | |
| JP2022504988A (ja) | Ｌｒｒｋ２の野生型および変異型のアザインドール阻害剤 | |
| JP2008521776A (ja) | コリン作動性リガンドとしての新規なジアザ二環式アリール誘導体 | |
| TWI715156B (zh) | 苯并咪唑化合物及其用於治療阿茲海默症或亨丁頓氏症之用途 | |
| JP2005536522A (ja) | ジアザビシクロノナン及び−デカン誘導体並びにこれをオピオイドレセプターリガンドとして使用する方法 | |
| CA3109623C (en) | Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease | |
| JP2000506871A (ja) | 複素環式化合物並びにその調製及び用途 | |
| KR20230172529A (ko) | 무스칼린 작용제 약물과 접합된 알파2 아드레날린 작용제 복합 약물 | |
| KR20140062471A (ko) | 알파 2 아드레날린 수용체의 조절물질로서의 n-(이미다졸리딘-2-일리덴)퀴놀린 유도체 | |
| JP2000509044A (ja) | ヘテロサイクリック化合物群 |